Peanut Allergen Aptamer
Neutralizing the Allergen at Its Source – Not Suppressing the Immune System
LEAD APTAMER: AYA22AR321
THERAPEUTIC AREA: Food Allergy / Peanut Allergy
STAGE: Late Lead Optimization (In Vivo Validations)
Peanut Allergen Aptamer
AYA22AR321
Neutralizing the Allergen at Its Source – Not Suppressing the Immune System
LEAD APTAMER: AYA22AR321
THERAPEUTIC AREA: Food Allergy / Peanut Allergy
STAGE: Late Lead Optimization (In Vivo Validations)
AYA22AR321 is a DNA aptamer designed to bind and neutralize the primary peanut allergens before they trigger an allergic reaction. The aptamer targets the major allergenic Ara h peanut proteins, preventing the immune cascade that leads to allergic responses.
This technology also powers FISTOQ™, an allergen-neutralizing formulation designed for surface decontamination and food safety applications.
The Unmet Need
Peanut allergy affects approximately 2% of children worldwide and is the leading cause of food-induced anaphylaxis. For patients and families, daily life involves constant vigilance to avoid accidental exposure in food preparation, restaurants, and shared environments.
Current Treatment Limitations
No existing therapy neutralizes the allergen itself or addresses environmental exposure risk.
OUR APPROACH — DIRECT ALLERGEN NEUTRALIZATION
AYA22AR321 was developed using Ayass Bioscience’s computational design platform and selected to bind the proteins responsible for peanut allergic reactions. The aptamer targets the major allergenic peanut Ara h proteins. By binding these allergens, AYA22AR321 prevents IgE crosslinking on mast cells and basophils, blocking the first step in the allergic cascade and preventing immune cell activation.
Studies demonstrate that allergen neutralization significantly reduces IgE-mediated degranulation in immune cell models. Detailed binding characterization and mechanistic studies are available in the published research.
